KaliVir Immunotherapeutics is developing next-generation oncolytic viral immunotherapies for cancer. Its Vaccinia Enhanced Template (VET) platform engineers vaccinia viruses that can be delivered intravenously, replicate selectively in tumors, and express therapeutic payloads. [1]
The company was co-founded in 2019 by Stephen Thorne, a former University of Pittsburgh professor of cell biology and immunology who serves as chief scientific officer. In August 2026 it announced the closing of a $14 million Series A extension, and it has a clinical trial collaboration and supply agreement with Roche. [1] [2]